-
Research Groups
-
Kedzierska Group
Professor Katherine Kedzierska’s team researches the immunity to viral infections, especially the newly emerged influenza viruses. Her work spans basic research – from mouse experiments to human immunity, through to clinical settings, with a particular focus on understanding universal CD8+ T cell immunity to influenza viruses. Her studies aim to identify key correlates of severe and fatal influenza disease in high-risk groups including children, the elderly and Indigenous Australians.
Other work areas include:COVID-19, Viral Infectious Diseases, Influenza
Current Projects
-
To define ‘universal’ influenza-specific CD8+ T-cell responses across different HLAs
Although CD8+ T-cells confer universal immunity to distinct influenza viruses and may limit influenza-induced mortality, the overall efficacy of human influenza A virus-specific CD8+ T cells directed at any conserved and/or variable epitopes remains unclear. Here, Katherine’s group aims to (i) understand influenza-specific CD8+ T-cell immunity across different HLAs; (ii) determine the efficacy of immunodominant CD8+ T-cell responses in humans; (iii) evaluate the conservation of immunogenic epitopes in birds, pigs and humans through analysis of viral evolutionary history (with Associate Professor Vijaykrishna from Duke-NUS in Singapore); (iv) understand immunity to clinically important but understudied influenza B viruses.
-
To identify correlates of severe and fatal influenza disease in high-risk groups
Enhanced susceptibility to influenza and exacerbated disease severity can reflect over-activation of the innate immune system, impaired humoral and cellular immunity and be influenced by host genetic factors (HLA or IFITM3). Understanding the key deficits that lead to severe disease in high-risk groups will provide insight into how immune interventions might minimise the incidence of severe influenza pneumonia. Katherine’s group studies the contributions of virological, immunological, clinical and host factors to susceptibility, clinical severity and outcome for different high-risk groups: (i) young children and the elderly (with Dr Crowe from Deepdene Surgery); (ii) Indigenous Australians (with Associate Professor Tong from Menzies in Darwin and Professor Miller from Griffith University in New South Wales), (iii) high-risk groups hospitalised through FluCAN (with Associate Professors Cheng and Kotsimbos) and Shanghai Public Clinical Hospital at Fudan University in China (with Professor Xu).
-
To unravel mechanisms underlying the early generation of human CTL memory
Though immunological memory is of pivotal importance for vaccine development and immunotherapy, the molecular and differentiation pathways central to the generation of (particularly) human CD8+ T-cell memory are poorly understood. Here, Katherine’s group aims to (i) establish the key factors driving the early establishment of influenza-specific T cell memory; (ii) To define molecular processes involved in CD27-mediated co-stimulation of human T cells. As memory is crucial for protection against recurrent infections, this work will provide novel insights into the generation and efficacy of human T cell memory populations and inform effective CD27-mediated stimulation for immunotherapy.
-
Preparing Animal Models
Once potential vaccine candidates have been identified for SARS-CoV-2, they must be tested in animals to predict the response in humans and determine overall efficacy, most likely in transgenic mice. Scientists at the Doherty Institute have experience in evaluating candidate vaccines for SARS (a related coronavirus) in animal models. Following this, the team will initiate human clinical trials with the Institute’s partners and other institutions as appropriate.
-
Passive Immunisation
After information has been identified on which part of the immune system leads to a full recovery (using rapid whole blood assays), passive immunisation scientists will isolate cross-reactive antibodies from infected patients and reproduce them at scale. These monoclonal antibodies will be directly transferred to a non-immune person to provide temporary protection.
-
The Doherty Institute COVID-19 Vaccine Development Initiative
The Doherty Institute COVID-19 Vaccine Development Initiative’s strategy is to pursue multiple avenues simultaneously, including developing active and passive vaccination platforms. Scientists will interrogate the immune response to the virus in people with moderate and severe disease to understand how the body naturally clears SARS-CoV-2. They will identify the difference between a good immune response (that clears infection) and a bad immune response (that makes people more unwell) by developing and utilising neutralization assays. For active immunisation, they will generate virus like particles (VLPs) that contain pieces of the SARS-CoV-2.
-
Natural History Studies
Natural History Studies explores the pathogenesis of COVID-19 to inform clinical care and to understand the immune response to the virus. This may provide clues to new therapeutics and vaccines.
Lab Team
-
Laboratory Head
-
Research Officer
-
NHMRC Peter Doherty Fellow
-
Research Fellow
-
Senior Research Fellow
-
Dr Zhongfang WangPostdoctoral fellow
-
Nicola BirdResearch Assistant
-
Hayley HayleyResearch Assistant
-
Emma GrantPhD student
-
Sergio Quinones ParraPhD student
-
Sneha SantPhD student
-
Simone NeussingPhD student
-
Jesseka ChaddertonPhD student
-
Barrow group
My lab is interested in how receptors expressed by immune cells distinguish normal healthy cells from malignant cells or pathogens. We want to understand how these receptors work together to regulate immune responses so we can design better clinical interventions.
-
Bedoui Group
The Bedoui Lab uses models of viral and bacterial infection to study how the innate and the adaptive immune system interact. Key foci are to understand how innate cells sense pathogens and how this information is integrated into protective adaptive T cell responses.
Other work areas include:Bacterial and Parasitic Infections
-
Brooks Group
Research in Andrew’s laboratory is largely centred on how natural killer cells and T cells impact the outcomes of viral infection, cancer and transplantation.
-
Chung group
The Chung group is interested in understanding the biophysical and functional properties of antibodies that are associated with protection against a range of infectious diseases, which will provide important insights to improve antibody-based vaccines and therapies.
Other work areas include:COVID-19, Viral Infectious Diseases
-
Corbett Group
Our team study mucosal-associated invariant T (MAIT) cells. We seek to understand how vitamin-based antigens are produced by microorganisms, how MAIT cells detect these antigens and how we can manipulate MAIT cell functions to improve outcomes in infectious and non-infectious diseases.
Other work areas include:Bacterial and Parasitic Infections
-
Gebhardt Group
Thomas’ group studies basic and translational aspects of immune responses in peripheral tissues. Their overall goal is to develop future vaccines and immunomodulatory therapies that target peripheral T cells for improved clinical outcomes in infection, inflammation and cancer.
-
Heath Group
Bill’s group’s cellular immunology research currently focuses on understanding killer T cell function with particular reference to improved vaccination strategies and understanding malarial disease.
Other work areas include:Malaria
-
Kallies Group
The Kallies group studies the molecular control of lymphocyte differentiation in response to antigen with a particular focus on T cells residing in non-lymphoid tissues, including tumors.
Other work areas include:Viral Infectious Diseases
-
Kent Group
Stephen’s group studies immunity to HIV, influenza and SARS-CoV-2. They are analysing a variety of vaccine strategies, including nanoparticle-based vaccines. They are studying a series of immune responses to gain better insights into protective immunity to important viral pathogens. They are developing monoclonal antibody therapies for HIV, influenza and SARS-CoV-2 to improve the treatment of these infections. The Kent group works very closely with Dr Amy Chung’s laboratory at the Doherty Institute.
-
Laura Mackay Group
The Mackay Group studies memory T cell responses, with a focus on the signals that control tissue-resident memory T cell differentiation, and a view to harness these cells to develop new treatments against infection, cancer and autoimmune conditions.
-
Lewin Group
The focus of the Lewin group is to understand why HIV infection persists on antiretroviral therapy and to develop new strategies to eliminate latency. The lab also researches factors that drive liver disease in HIV-hepatitis B virus co-infection. The lab is also actively involved in COVID in relation to pathogenesis, the use of primary tissue models, and developing therapeutics using gene editing strategies.
Other work areas include:Viral Infectious Diseases
-
Mantamadiotis Group
The Mantamadiotis group studies basic and translational aspects of molecular and cellular responses in brain cancer. Their overall goal is to develop future therapies, including immunomodulatory therapies that target the tumour cells and tumour infiltrating lymphocytes for improved clinical outcomes in cancer.
-
Matthew McKay Group
The McKay Group focuses on developing computational models, statistical and machine learning methods to address problems in infectious diseases and immunology. Current research is aimed at understanding virus evolution and immune escape and for identifying potent targets for next-generation vaccines.
-
McCluskey Group
MAIT cells respond to precursors of riboflavin, allowing the immune system to detect microbial invaders. The McCluskey group aims to understand their role in infection/inflammatory conditions and is tackling this question using mouse models, human tissue analysis and structural biology.
If you are interested to collaborate with us, please, feel free to get in touch. Please note that the human and mouse MR1 tetramers developed in our laboratory can now be ordered through the NIH tetramer core facility.
-
Mueller Group
Research in Scott’s group is focused on examining immune responses to both acute and chronic viral infections. A particular emphasis on T cell responses and interactions with antigen presenting cells and lymphoid tissue stromal cells is currently driving the group, as well as an interest in neuro-immune interactions.
Other work areas include:Malaria
-
Purcell Lab
Professor Damian Purcell’s research group investigates the HIV-1 and HTLV-1 human retroviruses that cause AIDS and leukaemia/inflammatory pathogenesis respectively. The lab studies their genetic structure and gene expression with a focus on defining the mechanisms that control viral persistence and pathogenesis. The molecular interplay of viral and host factors during viral infection and the innate and adaptive immune responses to viral infection are examined. These molecular insights are used to develop new antiviral and curative therapeutics, preventive prophylactic vaccines and passive antibody microbicides and therapeutics. Some of these patented discoveries have been commercialised and we are assisting with clinical trials.
Other work areas include:COVID-19, Viral Infectious Diseases, Bacterial and Parasitic Infections, HIV
-
Reading Group
Patrick’s group investigates how the body first detects and responds to respiratory viruses. They investigate viral attachment factors, cellular receptors and entry pathways, virus-induced activation of host genes and the mechanisms by which intracellular host proteins can block virus replication.
Other work areas include:COVID-19, Viral Infectious Diseases, Influenza
-
Robins-Browne Group
Research in Roy’s laboratory is partly focused on how E. coli causes diarrhoea, with the aims of identifying better ways to diagnose, treat and prevent these infections. Another theme is the development of new types of antibacterial agents.
Other work areas include:Enteric infections, Antimicrobial Resistance
-
Sullivan Group
Sheena’s epidemiology group at the WHO Collaborating Centre for Reference and Research on Influenza undertakes research into understanding influenza vaccine effectiveness and the validity of the methods used to estimate it. The group also provides technical assistance to partners in the Western Pacific Region of the WHO.
Other work areas include:COVID-19, Viral Infectious Diseases, Influenza
-
Tong Group
Steve’s group conducts clinical trials to optimise the treatment of infections due to methicillin-resistant Staphylococcus aureus and other bacterial pathogens. He also investigates the epidemiology and genomics of streptococcal infections, hepatitis B, influenza, and antimicrobial resistance in Australian Indigenous communities.
Other work areas include:Staphylococcus aureus, Viral Infectious Diseases, Antimicrobial Resistance, Bacterial and Parasitic Infections, Public Health
-
Vaccine and Immunisation Research Group
Based at the Doherty Institute, the Vaccine and Immunisation Research Group (VIRGo) works in partnership with the Murdoch Children’s Research Institute (MCRI, Infection and Immunity Theme). Our research enables us to advise policy makers on the optimal use of vaccines in national immunisation schedules, in pandemic influenza preparedness and response, and in vaccine safety. Our work provides practical bridges (translation) between theory and the real-world delivery of vaccine programs. VIRGo leads Vax4COVID, an alliance of experienced Australian vaccine clinical trial centres formed to facilitate the conduct of Phase II trials of SARS-CoV-2 vaccine candidates.
Other work areas include:COVID-19, Viral Infectious Diseases
-
Valkenburg Lab
The Valkenburg laboratory investigates viral immunity to emerging viruses with pandemic potential: influenza viruses and SARS-CoV-2. Our work spans randomised control vaccine trials, observational studies of infected patients and animal models to decipher immune correlates to drive novel translational outcomes for specific diagnostics, targeted therapeutics and next generation vaccines for public health impact.
Other work areas include:COVID-19, Viral Infectious Diseases, Public Health, Influenza
-
Villadangos Group
Jose’s group combines immunology, biochemistry and cell biology to study how the adaptive immune system detects pathogens and cancer, a process called Antigen Presentation. Their research is applicable to vaccine development, treatment of critically ill patients and the fight against cancer.
-
Wakim Group
Linda’s group’s main research focus is understating the mechanism of action and regulation of expression of antiviral proteins. Linda’s group also aims to characterise CD8 T cell responses within the lung following virus infection.
Other work areas include:Influenza
-
